Future oncology (London, England) · 2025
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shah Bijal D, Xue Mei, Furnback Wesley, Yang Keri
Аннотация
AIMS: This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.
MATERIALS & METHODS: A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.
RESULTS: 402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; P < 0.01) and displayed significantly higher adherence to treatment.
CONCLUSIONS: In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.
MATERIALS & METHODS: A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.
RESULTS: 402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; P < 0.01) and displayed significantly higher adherence to treatment.
CONCLUSIONS: In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.